Skip to content
Tallac Therapeutics, Inc
Tallac Therapeutics, Inc

News

Home
News
Publication and Data

Publication and Data

In Publication and DataPosted October 21, 2021

Tallac SITC 2021 Presentation

More
In Publication and DataPosted April 12, 2021

Tallac AACR 2021 Presentation

More
In Publication and DataPosted March 12, 2021

AACR 2021 presentation on preclinical data for TAC-001

More
In Publication and DataPosted November 5, 2020

SITC 2020 Presentation

More

Categories

  • Latest News (4)
  • Publication and Data (4)

Recent Posts

  • Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
  • Tallac SITC 2021 Presentation
  • Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
  • Tallac AACR 2021 Presentation
  • AACR 2021 presentation on preclinical data for TAC-001

Archives

  • May 2022
  • October 2021
  • April 2021
  • March 2021
  • December 2020
  • November 2020
Tallac Therapeutics, Inc
  • (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Linkedin-in Envelope

Copyright © 2020-2022 Tallac Therapeutics, Inc. All Rights Reserved.